SGLT-2 inhibitors
https://themeditary.com/dosage-information/farxiga-dosage-417.html

Farxiga Dosage

Drug Detail:Farxiga (Dapagliflozin)

Generic Name: DAPAGLIFLOZIN PROPANEDIOL 5mg

Dosage Form: tablet, film coated

Drug Class: SGLT-2 inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions FAQ

Prior to Initiation of FARXIGA

Assess renal function prior to initiation of FARXIGA therapy and then as clinically indicated [see Warnings and Precautions (5.2)].

Assess volume status and, if necessary, correct volume depletion prior to initiation of FARXIGA [see Warnings and Precautions (5.2) and Use in Specific Populations (8.5, 8.6)].

​Recommended Dosage

​See Table 1 for dosage recommendations based on estimated glomerular filtration rate (eGFR).

Table 1: Recommended Dosage
*
FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m2. FARXIGA is likely to be ineffective in this setting based upon its mechanism of action.

eGFR
(mL/min/1.73 m2)

Recommended Dose

eGFR 45 or greater

To improve glycemic control, the recommended starting dose is 5 mg orally once daily. Dose can be increased to 10 mg orally once daily for additional glycemic control*.

For all other indications, the recommended starting dose is 10 mg orally once daily.

eGFR 25 to less than 45

10 mg orally once daily*.

eGFR less than 25

Initiation is not recommended, however patients may continue 10 mg orally once daily to reduce the risk of eGFR decline, ESKD, CV death and hHF.

On dialysis

Contraindicated.

hHF: hospitalization for heart failure, CV: Cardiovascular, ESKD: End Stage Kidney Disease.
Share this Article
Latest News
Related Drugs